Clinical trial
A Phase III Clinical Trial With Randomized, Double-blinded, Controlled Design as Well as Bridging Design to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Children Aged 36-71 Months
NCT03909074 is registered in ClinicalTrials.gov with Sinovac Biotech Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III Clinical Trial With Randomized, Double-blinded, Controlled Design as Well as Bridging Design to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Children Aged 36-71 Months
- Lead sponsor
- Sinovac Biotech Co., Ltd
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 10, 2019
- Completion date
- November 13, 2019
- Enrollment
- 900 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.